BSW Wealth Partners bought a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 1st quarter, HoldingsChannel.com reports. The fund bought 12,410 shares of the company’s stock, valued at approximately $227,000.
A number of other hedge funds have also recently modified their holdings of TAK. Concord Wealth Partners increased its holdings in shares of Takeda Pharmaceutical by 61.7% during the 1st quarter. Concord Wealth Partners now owns 1,712 shares of the company’s stock valued at $31,000 after acquiring an additional 653 shares during the last quarter. Pinnacle Bancorp Inc. boosted its stake in Takeda Pharmaceutical by 172.9% during the 1st quarter. Pinnacle Bancorp Inc. now owns 2,527 shares of the company’s stock valued at $46,000 after purchasing an additional 1,601 shares during the period. Bessemer Group Inc. bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $62,000. Parallel Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 25.1% in the 1st quarter. Parallel Advisors LLC now owns 4,758 shares of the company’s stock worth $87,000 after acquiring an additional 954 shares during the period. Finally, Captrust Financial Advisors lifted its position in shares of Takeda Pharmaceutical by 45.6% in the 4th quarter. Captrust Financial Advisors now owns 6,122 shares of the company’s stock worth $111,000 after acquiring an additional 1,918 shares during the period. 3.40% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical stock opened at $16.85 on Thursday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.53 and a quick ratio of 1.10. The company has a market cap of $53.17 billion, a P/E ratio of 8.46 and a beta of 1.06. Takeda Pharmaceutical Company Limited has a one year low of $15.30 and a one year high of $19.97. The stock’s 50 day moving average is $16.95.
A number of analysts have commented on the company. Jefferies Financial Group downgraded Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday, April 5th. Zacks Investment Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 22nd. Finally, JPMorgan Chase & Co. downgraded Takeda Pharmaceutical from an “overweight” rating to a “neutral” rating in a research report on Monday, April 19th.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines.
Featured Article: Average Daily Trade Volume – What You Need to Know
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.